Nasdaq

Alterity Therapeutics Announces Positive ATH434 Phase 2 Trial Results in Multiple System Atrophy Led By Robust Clinical Efficacy

MELBOURNE, Australia and SAN FRANCISCO, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing ...
Seeking Alpha

Alterity Therapeutics Presents Encouraging New Data from its ATH434 Phase 2 Trial in Multiple System Atrophy at the American Academy of Neurology Annual Meeting

MELBOURNE, Australia and SAN FRANCISCO, April 10, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying ...
PMLive

Lundbeck completes patient randomisation for phase 3 trial for multiple system atrophy treatment

The last patient in Lundbeck’s phase 3 clinical trial, MASCOT, has been randomised ahead of schedule in a study evaluating amlenetug as a potential treatment for multiple system atrophy (MSA). The ...
Nasdaq

Alterity Therapeutics Reports Positive Interim Data from ATH434-202 Phase 2 Clinical Trial in Multiple System Atrophy

MELBOURNE, Australia and SAN FRANCISCO, July 17, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing ...
Morningstar

Tiziana Life Sciences Doses First Patient in Phase 2a Trial of Intranasal Foralumab for Multiple System Atrophy

Multiple System Atrophy is a rare and debilitating disorder involving the progressive loss of nerve cells in several areas of the brain. Symptoms may include severe problems with movement, balance, ...
Morningstar

Cytora Reports Phase 1 Data of Stem Cell Treatment for Multiple System Atrophy | Morningstar

YOKNEAM, Israel, May 19, 2025 /PRNewswire/ -- Cytora, a clinical stage company developing unique stem cell treatments based on human Oral Mucosa Stem Cells (hOMSC), reported today data of an ongoing ...
Pharmabiz

Lundbeck announces last patient randomized ahead-of-schedule in phase 3 MASCOT clinical trial

Lundbeck announces last patient randomized ahead-of-schedule in phase 3 MASCOT clinical trial: Valby, Denmark Wednesday, March 11, 2026, 13:00 Hrs [IST] H. Lundbeck A/S (Lundbeck) ...

Alterity Therapeutics Taps Vanderbilt Neurologist as Chief Medical Advisor Ahead of Phase 3 MSA Trial

Detailed price information for Alterity Therapeutics Ltd (PRNAF) from The Globe and Mail including charting and trades.
Insider Monkey

Alterity Therapeutics Limited (ATHE) Announces Positive Topline Data From Phase 2 Trial of ATH434 in Multiple System Atrophy

Alterity Therapeutics Limited (NASDAQ:ATHE) is among the 12 Best Australian Stocks to Buy Right Now. The company recently reported positive topline data from an open-label Phase 2 clinical trial of ...
clinicaladvisor.com

Multiple System Atrophy: A Common Form of Atypical Parkinsonism

Currently no disease-modifying or neuroprotective treatments exist for MSA, nor are there effective medications to treat the cerebellar ataxia in MSA-C or the parkinsonian features in MSA-P. Physical ...
Seeking Alpha

Alterity Therapeutics Reports Positive Topline Data from Open-Label Phase 2 Clinical Trial of ATH434 in Multiple System Atrophy

MELBOURNE, Australia and SAN FRANCISCO, July 28, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying ...